Phaseline

Companies › Aperta Biosciences

Aperta Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
APT-001 topical ophthalmic ointment (spinosad 1.8%)
Spinosad is a natural insecticide/acaricide that kills parasites and mites; mechanism in b
–Phase 2Blepharitis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06720896APT-001 topical ophthalmic ointment (spinosad 1.8%)Phase 2BlepharitisOphthalmologyJul 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Qlaris Bio Jiangsu Jingze Biopharmaceutical ONL Therapeutics BioTheraVision Vantage Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.